GLG News by Class Action Experts: Lawyers (US)

President-elect owes Big Labor a bone for its enormous support in getting him elected and Labor wants enactment of the Employee Free Choice Act more than any other political favor.  The odds would seem to favor Labor, but in turn would spell disaster for the business community.  For the first...

Public anger against banks, coupled with merchant anger against bankcard issuers, will force the Obama Administration and Congress to consider legislation to resolve the merchand-card industry impasse on how, if at all, interchange fees should be calculated.  While policy makers on the one...

Visa & MasterCard's $2.75B settlement of the antitrust suit against them by Discover should have relevance to the interchange lawsuit against them by their merchants.  It suggests either great vulnerability to the merchants or a strategic act by the networks to remove Discover as a distraction. ...

The article underlines the extent to which governments will go to retrun banks to profitability.  Accordingly, EU policy makers will not enforce  state aid laws that would otherwise prohibit capital infusions into local banks by state regulators and will favorably consider less aggressive...

It should be no surprise that the subprime/ARS collapse has generated waves of class action lawsuits by shareholders.  And that they appear to have merit.  But that doesn't mean courts will give the plaintiffs the WMD of a class action status.  Ten years ago that would have been...

The DoJ amicus brief to the Supreme Court in a telecommunications case hints at a more relaxed view about the applicability of antitrust law to pricing decisions by regulated companies.  A key accusation in the bankcard interchange cases is that competing regulated banks on Visa...

The new DoJ antitrust guidelines significantly water down monopoly, per se liability, competition and tie-in standards that have propelled government enforcement and private lawsuits by retailers in recent years against Visa, MasterCard and their issuers.  Undoubtedly, the defendants will point...

The Lafferty study indicates that forced reductions of bankcard interchange fees in Australia have not significantly harmed issuer or network profits.  This is the exact opposite of what industry representatives had predicted.  If Lafferty is on target, interchange pricing...

The financial responsibity will lie with Baxter, not the FDA.  Perhaps moral or political responsibility (and fall out) will rest with the FDA, but that is of no help to those harmed by the Heparin.  Their only recourse is to sue the manufacturer.

Under the current administration, the FDA has tried to use drug approval as a shield.  In some cases, the current court has held warning approval to bar lawsuits.  However, this can be remedied by Congress explicitly clarifying that the FDA approval of a drug does not preempt state law....